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Abstract 
We report on a two-phase test performed to assess the ability of the ultrasound-based B-mode acquisition and targeting (BAT) trans-
abdominal system to identify non-dedicated fiducial markers implanted into the prostate gland for subsequent image-guided radiotherapy.
Although further investigation is warranted in order to identify the optimal echogenic marker and to define its potential use for image-
guided radiotherapy in prostate cancer patients, we demonstrate the feasibility of the BAT system for the visualization of non-ultrasound-
dedicated markers. 
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Introduction 
Dose escalation improves biochemical and clinical control in 
prostate cancer treated with external beam radiotherapy 
(EBRT), as demonstrated by several retrospective and 
prospective randomized studies [1–5]. Whenever a dose of >70 
Gy is administered, the irradiated volume should be reduced in 
order to avoid excessive damage to the surrounding normal 
tissue. In clinical practice, such volume reduction has become 
feasible with the introduction of image-guided radiotherapy 
(IGRT). Various systems are routinely used in many 
departments for daily localization of the prostate during 
radiotherapy, i.e. implanted fiducial markers with x-ray, on-
board computed tomography (CT) or dedicated ultrasound (US) 
IGRT systems. Among these methods, the US system is 
probably the fastest. Several authors report that the fiducial 
marker-based IGRT is the most reliable, although it does not 
allow for soft tissue (prostate, seminal vesicles, rectum, urinary 
bladder) imaging [6]. 
In June 2005, the B-mode acquisition and targeting (BAT) 
transabdominal US System (Nomos, USA) was installed in our 
department. It is a computer-assisted cart-based system located 
in the treatment room enabling daily patient setup. 
In a previous study [7], we evaluated the feasibility and 
accuracy of BAT-based prostate localization. Ten patients with 
localized prostatic adenocarcinoma were treated with three-
dimensional conformal radiotherapy (3D-CRT) to the dose of 72 
Gy/30 fractions prescribed in the ICRU point (International 
Commission of Radiation Units). Daily US-based IGRT was 
compared to the electronic portal imaging (EPI) and CT-based 
alignment. We demonstrated that the BAT system ensures that 
the relative positions of the isocentre remain the same during 
treatment and as outlined in the treatment plan, even if the 
reliability of alignment is patient dependent. The average BAT-
determined misalignments were small, confirming the 
prevalence of random errors in 3D-CRT. The limitations of the 
BAT system include inaccuracy of comparing images acquired 
by two different modalities (CT for planning and daily US 
images for setup), possible prostate displacement induced by 
US-probe pressure and operator dependence [8]. According to 
the literature, an average probe displacement of 12 mm results 
in an average prostate displacement of 3 mm [9,10]. Prostate 
movement due to probe pressure is mostly in the 
anteroposterior (AP) direction, but systematic shifts have been 
observed also in the craniocaudal direction [11,12].  
An unpublished study on a series of 25 patients affected by 
localized prostate cancer treated at our department with hypo-
fractionated 3D-CRT and daily BAT-based prostate localization 
showed a mean inter-patient systematic displacement of the 
prostate of 2.4 mm in the AP direction, probably related to the 
different US probe pressures used. 
The purpose of this study was to test the potential role of two 
different commercially available fiducial markers in the US-
based IGRT for prostate cancer. In the future, the introduction of 
fiducial markers for US-based IGRT might reduce both 
operator-dependent variations and potential influence of 
unfavourable patient anatomy, such as obesity or a small 
prostate located behind the pubic symphysis (patient 
dependence). Moreover, errors introduced during the learning 
curve for inexperienced US operators could be reduced. 
 
Materials and methods 
We tested the ability of the BAT system to visualize a set of 
standard gold fiducial markers (VisiCoil, RadioMed Corporation, 
USA; 0.75 mm in diameter and 10 mm in length) already used 
in our department for ExacTrac prostate cancer IGRT. In 
ExacTrac patients, the two VisiCoil fiducial markers are 
introduced into the prostate seven days before the simulation. 
For the purpose of the present study, we performed the BAT 
procedure in one patient enrolled in our ExacTrac x-ray 
hypofractionated protocol (2.7 Gy fraction; five fractions/week; 
26 fractions, total dose of 70.2 Gy). 
The second part of our study involved the evaluation, in a low-
risk prostate cancer patient, selected for permanent seed 
implant brachytherapy, of the ability of the BAT system to 
visualize a different type of commercially available marker 
(CyberMark
TM Fiducial Marker, Civco, USA, 1 mm in diameter 
and 5 mm in length). 
A dedicated informed consent was obtained. The implantation 
of the fiducial markers, near the left and right base positions, 
was performed using the same template-based brachytherapy 
technique. 
Under epidural anaesthesia, the bladder was catheterized and 
filled with 200 cc of saline solution. A well-trained operator 
performed a preliminary transabdominal US examination, using 
the BAT system, to check prostate visibility. 
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Figure 1: US-images and simulation-CT contours of the bladder, prostate and rectum in the IGRT patient with VisiCoil markers implanted (white 
arrows). 
 
Figure 2: US and x-ray images of the CyberMark
TM markers (dotted circles) in the brachytherapy patient.
Each marker was implanted via a transperineal percutaneous 
approach, using a dedicated preloaded needle under real-time 
transrectal US guidance. 
At the end of the procedure, the same operator performed a 
new transabdominal US evaluation with the BAT system to 
visualize the markers inside the prostate and thereafter the 
planned brachytherapy procedure was started. 
 
Results 
These preliminary tests demonstrated the ability of the BAT 
system to visualize non-US-dedicated markers. 
The alignment based on the fusion of the fiducial marker images 
coming from the simulation-CT and BAT procedure was 
feasible. The marker-based shift was equal to the soft-tissue
imaging-based shift. The quality of the marker US image was 
satisfactory (Figure 1). 
The time needed for implanting the markers in the 
brachytherapy patient was about 20 minutes and did not affect 
the accurate completion of the planned permanent seed implant 
(Figure 2). 
The patient experienced no complications or discomfort after 
the two procedures. 
 
Discussion 
We have demonstrated the capacity of the BAT system to 
visualize different types of standard and commercially available 
non-US-dedicated fiducial markers. 
The marker implantation is an invasive procedure with a 
potential for discomfort, possible bleeding, infection and
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prostate deformation [13]. However, if it proves applicable in 
clinical practice for US-based IGRT, as has been already 
demonstrated for cone-beam CT IGRT, it could reduce the 
subjectivity involved in interpreting the soft tissue image. In this 
way, the need for additional radiation doses from MV or kV 
radiography could be avoided. [14]. 
Moreover, the cost of US-based IGRT, even when fiducials are 
used, should be competitive with the CT or x-ray-based IGRT 
procedures. 
 
Conclusions 
Although the feasibility of using the BAT system with fiducial 
markers has been clearly demonstrated, new echogenic 
fiducials with different technical design should be tested to in 
order to facilitate the transabdominal US image evaluation [15]. 
Their construction material (gold, titanium, silver, carbon, etc.) 
should be carefully chosen to increase the proportion of US 
signal reflected depending on their different acoustic 
impedances. We believe that the results of this preliminary 
investigation warrant a more complete clinical study of the 
practical applicability of radiopaque echogenic markers in 
patients selected for daily BAT-based IGRT. Such a procedure 
might reduce inter-fraction and inter-observer discrepancies. 
Future studies, including 3-D-US technology, are warranted in 
order to increase the accuracy of US-based IGRT for prostate 
cancer. 
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